Nordicus Partners announces board changes, expands from three to five members

BEVERLY HILLS - Nordicus Partners Corporation (OTCQB:NORD), a $33.8 million market cap company whose stock has declined 74% over the past year, announced Thursday that Henrik Keller has resigned from its Board of Directors to pursue other interests, while the company has expanded its board from three to five members.

The business accelerator and holding company, which specializes in helping Nordic and U.S. life sciences companies establish themselves in the American market, has appointed three new directors: Torben Jensen, Kim T. Mücke, and Andrew J. Ritter. According to InvestingPro data, the company faces financial challenges with negative EBITDA of $2.91 million in the last twelve months.

Jensen, already a major shareholder in Nordicus, brings over 35 years of finance experience and has previously served as CEO and Chairman of two Nasdaq-listed companies. From 2019 to 2024, he was a Senior Partner at GK Partners ApS, a corporate finance house and major Nordicus shareholder.

Mücke, a Danish state-authorized public accountant until 2025, was a partner at Deloitte Denmark from 2002 to 2022 and later served as Head of Corporate Clients for BDO Denmark. He will chair the board’s Audit Committee.

Ritter currently serves as CEO of Cairns Health, an AI-powered remote care solutions company. His previous experience includes CEO roles at Docbot and Ritter Pharmaceuticals, which he founded.

"We thank Henrik Keller for his service to our company," said Henrik Rouf, CEO of Nordicus, in the press release statement.

Nordicus describes itself as the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. In 2024, the company acquired Danish biotech firms Orocidin A/S and Bio-Convert A/S, which are developing treatments for periodontitis and oral leukoplakia, respectively. The company is currently trading below its Fair Value, with its next earnings report due in 11 days. Unlock detailed financial analysis and more insights with InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.